Original Paper

Plasma 1,5-Anhydroglucitol Concentration in Patients with End-Stage Renal Disease with and without Diabetes Mellitus
M. Emoto^a, T. Tabata^b, T. Inoue^b, Y. Nishizawa^a, H. Morii<sup>a

a</sup>Second Department of Internal Medicine, Osaka City University Medical School, Osaka;
^bInoue Hospital, Suita, Osaka, Japan

Address of Corresponding Author

Nephron 1992;61:181-186 (DOI: 10.1159/000186868)

  Key Words

• 1,5-Anhydroglucitol
• Diabetes mellitus
• Glycemic parameters
• End-stage renal disease
• Dialysis
• Renal tubular damage

  Abstract

The plasma concentration of 1,5-anhydroglucitol, a new clinical marker of glycemic control in diabetic patients, was evaluated as a marker of glycemia in 83 diabetic and nondiabetic patients with end-stage renal disease. Plasma 1,5-anhydroglucitol concentration decreased and correlated inversely with blood glucose, hemoglobin A_1c, or fructosamine in 48 diabetic patients with normal renal function. In 13 nondiabetic patients with end-stage renal disease not on dialysis, plasma 1,5-anhydroglucitol concentrations were lower than in 23 healthy subjects (6.22 ± 2.10 vs. 24.20 ± 7.50 µg/ml, respectively). The plasma concentration of 1,5-anhydroglucitol concentration in nondiabetic patients with end-stage renal disease was inversely correlated to the urinary N-acetyl--D-glucosaminidase activity (r = -0.634) but not to blood glucose, hemoglobin A_1c, or fructosamine. Renal tubular damage may contribute to the low plasma concentration of 1,5-anhydroglucitol in this group. The plasma concentrations of this polyol decreased in both diabetic (4.63 ± 1.08 µg/ml) and nondiabetic patients on hemodialysis (4.71 ± 0.87 µg/ml). In these two groups, there was no correlation between plasma concentration of this polyol and blood glucose, hemoglobin A_1c, or fructosamine. The plasma concentration of 1,5-anhydroglucitol decreased after a single hemodialysis session. The results showed that impaired renal function and removal of 1,5-anhydroglucitol by dialysis may contribute to its decreased concentration in patients with end-stage renal disease, but that glycemic control does not. Therefore, we should consider renal function when we use plasma 1,5-anhydroglucitol concentration as a marker of glycemic control in diabetic patients.

Copyright © 1992 S. Karger AG, Basel

  Author Contacts

Masanori Emoto, MD, Second Department of Internal Medicine, Osaka City University Medical School, 1-5-7, Asahi-machi, Abeno-ku Osaka 545 (Japan)

  Article Information

Accepted: September 3, 1991
Published online: December 11, 2008
Number of Print Pages : 6